www.fiercebiotech.com Open in urlscan Pro
104.18.0.165  Public Scan

Form analysis
1 forms found in the DOM

POST /medtech/jpm-2022-fosun-pharma-invests-insilico-medicine-for-its-ai-drug-discovery-programs

<form action="/medtech/jpm-2022-fosun-pharma-invests-insilico-medicine-for-its-ai-drug-discovery-programs" method="post" id="search-api-page-block-form-searcha" accept-charset="UTF-8">
  <div class="js-form-item form-item js-form-type-search form-type-search js-form-item-keys form-item-keys form-no-label">
    <label for="edit-keys" class="visually-hidden">Search</label>
    <input title="Enter the terms you wish to search for." placeholder="New Search" data-drupal-selector="edit-keys" type="search" id="edit-keys" name="keys" value="" size="15" maxlength="128" class="form-search">
  </div>
  <input autocomplete="off" data-drupal-selector="form-eso3ddkht2hqr6uju-1m76fmrmevgjcpgfff0ita-pk" type="hidden" name="form_build_id" value="form-eSo3DDkHt2HQR6uJu-1m76fMrMEvgjCPGFFf0ItA-Pk">
  <input data-drupal-selector="edit-search-api-page-block-form-searcha" type="hidden" name="form_id" value="search_api_page_block_form_searcha">
  <div data-drupal-selector="edit-actions" class="form-actions js-form-wrapper form-wrapper" id="edit-actions"><input class="search-form__submit button js-form-submit form-submit" data-drupal-selector="edit-submit" type="submit" id="edit-submit"
      name="op" value="Search">
  </div>
</form>

Text Content

Advertisement



Fierce Biotech Continues Here ▼







Skip to main content


MAIN NAVIGATION

 * Biotech
 * Research
 * CRO
 * MedTech
 * Trending Topics
   * Cell & Gene Therapy
   * COVID-19
   * Oncology
   * Emerging Biopharma
 * Special Reports


MAIN NAVIGATION - MOBILE

 * Biotech
 * Research
 * CRO
 * MedTech
 * Trending Topics
   * Cell & Gene Therapy
   * COVID-19
   * Oncology
   * Emerging Biopharma
 * Special Reports


   TOP MENU
   
    * Fierce Events
    * FiercePharma
    * Jobs
    * Resources
    * Webinars
    * Industry Events
    * Subscribe

   Twitter LinkedIn Facebook

Search

Enclose phrases in quotes. Use a + to require a term in results and - to exclude
terms.
Example: +water -Europe


TOP MENU

 * Fierce Events
 * FiercePharma
 * Jobs
 * Resources
 * Webinars
 * Industry Events
 * Subscribe

Twitter LinkedIn Facebook


Fierce Biotech's JPM 2022 coverage all in one place

Dealmaking, R&D updates and biotech trends: Follow our coverage of the virtual
JPM 2022

MEDTECH




JPM 2022: FOSUN PHARMA INVESTS IN INSILICO MEDICINE FOR ITS AI DRUG DISCOVERY
PROGRAMS

by Conor Hale |
Jan 13, 2022 11:40am
Fosun Pharma tapped Insilico's AI for work on four disease targets, and also
signed on to co-develop Insilico's QPCTL program aimed at a checkpoint protein
in immuno-oncology. (Freeman Zhou / Unsplash)
ShareFacebookTwitterLinkedInEmailPrint

The artificial intelligence-powered molecule designer Insilico Medicine has
collected another international drug discovery partnership, with the
Shanghai-based Fosun Pharma signing on for work on four disease targets.



The collaboration includes an upfront $13 million payment to kick off the
company’s R&D projects plus an equity investment in Insilico of an undisclosed
amount, according to an announcement during the J.P. Morgan Healthcare
Conference.

In addition to the four targets, Fosun will also assist in co-developing
Insilico’s QPCTL program, aimed at a checkpoint protein in immuno-oncology.
Insilico will work to deliver a preclinical candidate and prepare it for human
studies, while Fosun Pharma will conduct clinical trials and develop the drug
globally. The two companies have also agreed to milestone-based payments and to
share commercial profits.




RELATED: Insilico Medicine scores $255M venture round to move AI-designed drugs
into human clinical trials

Over the course of 2021, Insilico demonstrated that using its AI programs, it
could uncover a novel target and then identify a potential new drug for
pulmonary fibrosis in a total of 18 months, and at a total cost of about $2.6
million.

About nine months later, the company announced it had taken that drug into its
first trial in humans, with healthy volunteers in an Australian study receiving
limited, intravenous doses of ISM001-055, a small molecule inhibitor aimed at
the chronic lung disease.

Insilico has said the compound has shown preliminary results in activating the
myofibroblast cells essential for repairing damaged tissues. It also noted that
the drug’s target could be potentially applied to other fibrotic diseases such
as in the kidneys or liver.

RELATED: BioNTech, Fosun Pharma eye 1B doses of COVID-19 vaccine capacity with
new China JV

Previously, Insilico inked research projects with Boehringer Ingelheim, Huadong
Medicine and others. 

The deal with Boehringer Ingelheim spans areas such as heart failure, tropical
diseases, cystic fibrosis and muscular dystrophy and includes a special focus on
connecting with scientific talent in Asia, with Insilico being largely based out
of Hong Kong and has offices around the globe.

The alliance with the Chinese pharma Huadong, meanwhile, focuses on disease
targets previously considered undruggable. Huadong will provide its drug
discovery and screening characterization platform, while Insilico's machine
learning platform will aim to identify small molecules that may increase the
chances of succeeding against hard-to-hit cancer targets.

Read more on
artificial intelligence drug discovery JPM 2022 immuno-oncology Insilico
Medicine Fosun Pharma




RESOURCE CENTER

WEBINAR


EXPAND DRUG MARKET ACCESS IN 3 KEY STEPS

CASE STUDY


COMMERCIALIZING DIAGNOSTIC TESTS: ACHIEVING COMMERCIAL SUCCESS WITH A COMPLETE
MARKET VIEW

WEBINAR


EXPLORING RARE DISEASE THROUGH A DATA-DRIVEN LENS




ABOUT THE AUTHOR

Conor Hale
Associate Editor
chale@questex.com
https://twitter.com/conorhale




 * GENERAL
   * Home
   * Privacy
   * Terms of Use
   * RSS
 * CONTACT
   * Advertise
   * About Us
 * NEWSLETTERS
   * Subscribe
 * Connect
   * 
   * 
   * 

© 2021 Questex LLC. All rights reserved. 3 Speen Street, Suite 300, Framingham,
MA 01701

Reproduction in whole or part is prohibited.



✓
Thanks for sharing!
AddToAny
More…

x